Mangrove Partners acquired a new stake in shares of Zafgen, Inc. (NASDAQ:ZFGN) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 559,985 shares of the biopharmaceutical company’s stock, valued at approximately $1,971,000. Zafgen makes up approximately 0.3% of Mangrove Partners’ portfolio, making the stock its 26th biggest position. Mangrove Partners owned about 2.04% of Zafgen as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Zafgen by 15.7% during the second quarter. Vanguard Group Inc. now owns 883,838 shares of the biopharmaceutical company’s stock valued at $3,102,000 after buying an additional 119,902 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Zafgen by 31.8% during the second quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock valued at $2,050,000 after buying an additional 140,848 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Zafgen by 1,701.5% during the second quarter. Goldman Sachs Group Inc. now owns 197,287 shares of the biopharmaceutical company’s stock valued at $692,000 after buying an additional 186,336 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Zafgen during the first quarter valued at approximately $840,000. Finally, OxFORD Asset Management LLP boosted its position in shares of Zafgen by 65.0% during the third quarter. OxFORD Asset Management LLP now owns 171,112 shares of the biopharmaceutical company’s stock valued at $585,000 after buying an additional 67,394 shares during the last quarter. Hedge funds and other institutional investors own 48.70% of the company’s stock.

Zafgen, Inc. (NASDAQ ZFGN) opened at $3.94 on Monday. Zafgen, Inc. has a 1 year low of $3.11 and a 1 year high of $5.46.

Zafgen (NASDAQ:ZFGN) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.12. equities analysts forecast that Zafgen, Inc. will post -2.02 EPS for the current year.

In other Zafgen news, Director Frances K. Heller acquired 10,000 shares of the business’s stock in a transaction on Friday, October 13th. The shares were acquired at an average price of $3.90 per share, with a total value of $39,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 21.20% of the stock is currently owned by insiders.

Several brokerages recently issued reports on ZFGN. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research report on Saturday, November 11th. ValuEngine cut Zafgen from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $6.63.

COPYRIGHT VIOLATION NOTICE: “559,985 Shares in Zafgen, Inc. (ZFGN) Acquired by Mangrove Partners” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/12/11/559985-shares-in-zafgen-inc-zfgn-acquired-by-mangrove-partners.html.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Stock Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related stocks with our FREE daily email newsletter.